机构:[1]Thyroid Disease Diagnosis and Treatment Center,First Affiliated Hospital of Kunming Medical University.昆明医科大学附属第一医院外科科室普通外科普通外五科(甲状腺疾病诊疗中心)[2]Kunming Medical University,the First Clinical Medical School of Kunming Medical University,Yunnan,China.昆明医科大学附属第一医院
第一作者机构:[1]Thyroid Disease Diagnosis and Treatment Center,First Affiliated Hospital of Kunming Medical University.[2]Kunming Medical University,the First Clinical Medical School of Kunming Medical University,Yunnan,China.
通讯作者:
推荐引用方式(GB/T 7714):
Liu Bin,Peng Ying,Su Yanjun,et al.Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer[J].Anti-Cancer Drugs.2024,35(8):741-751.doi:10.1097/CAD.0000000000001626.
APA:
Liu Bin,Peng Ying,Su Yanjun,Diao Chang,Qian Jun...&Cheng Ruochuan.(2024).Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer.Anti-Cancer Drugs,35,(8)
MLA:
Liu Bin,et al."Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer".Anti-Cancer Drugs 35..8(2024):741-751